investorscraft@gmail.com

Intrinsic value of Inogen, Inc (INGN)

Previous Close$27.71
Intrinsic Value
Upside potential
Previous Close
$27.71

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh28.99 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %16.1NaN
Revenue, $358NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m349NaN
Operating income, $m9NaN
EBITDA, $m31NaN
Interest expense (income), $mNaN
Earnings before tax, $m9NaN
Tax expense, $m15NaN
Net income, $m-6NaN

BALANCE SHEET

Cash and short-term investments, $m246NaN
Total assets, $m490NaN
Adjusted assets (=assets-cash), $m244NaN
Average production assets, $m148NaN
Working capital, $m268NaN
Total debt, $m27NaN
Total liabilities, $m119NaN
Total equity, $m370NaN
Debt-to-equity ratio0.072NaN
Adjusted equity ratio0.525NaN

CASH FLOW

Net income, $m-6NaN
Depreciation, amort., depletion, $m22NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m7NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-5NaN
Free cash flow, $m12NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m268
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount